(PharmaNewsWire.Com, January 05, 2018 ) The Latin America Diabetic Retinopathy Market has been estimated at USD 0.79 billion in 2016 and is projected to reach USD 1.15 billion by 2021, at a CAGR of 7.69% during the forecast period from 2016 to 2021. Latin America is projected to showcase profitable growth in the forecast period. Favourable government initiatives and clinical guidelines are expected to increase the diagnosis and treatment rate, thereby fuelling the growth of the market in the region.
Diabetes is the long-lasting condition associated with abnormally high level of glucose in the blood. Deficient or non-production of insulin in pancreas causes diabetes. Diabetic retinopathy is the most common complication of diabetic that affects eyes. People suffering from diabetes type I and II have threat of developing diabetic retinopathy. Swelling or leakage of blood vessels of retina is the causes of the disease.
Increasing occurrences of diabetes, growing geriatric population base and the rising demand for early detection are some high influence rendering drivers of the diabetic retinopathy market. Furthermore, refining healthcare infrastructure, increasing demand for cost-effective and safe treatment and rising focus of market players on developing regions are also predicted to propel market growth.
Market Segmentation • By Type of Treatment • Anti-Vascular Endothelial Growth Factor (VEGF) drug • Intraocular Steroid Injection • Laser Surgery • Vitrectomy By Indication • Non-Proliferative Diabetic Retinopathy (NPDR) • Mild • 1.2 Moderate • Severe • Proliferative Diabetic Retinopathy (PDR) By End Users • Hospitals • Ophthalmic Clinics • Ambulatory Surgical Centers
The Latin America Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy. By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Amplified incidence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are projected to propel the growth of non-proliferative diabetic retinopathy market share. In addition, based on geography the Latin America Diabetic Retinopathy Market is analysed under the regions of Brazil, Argentina and Mexico.
The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: abhishek@marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
